Pine Valley Investments Ltd Liability Co Sells 10,669 Shares of IQVIA Holdings Inc. $IQV

Pine Valley Investments Ltd Liability Co trimmed its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 20.1% during the first quarter, Holdings Channel reports. The firm owned 42,533 shares of the medical research company’s stock after selling 10,669 shares during the period. Pine Valley Investments Ltd Liability Co’s holdings in IQVIA were worth $7,254,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of IQV. Boston Partners bought a new position in shares of IQVIA during the 3rd quarter worth approximately $676,698,000. Norges Bank bought a new stake in IQVIA in the fourth quarter valued at $497,445,000. Victory Capital Management Inc. raised its stake in IQVIA by 2,628.1% during the fourth quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock worth $377,670,000 after acquiring an additional 1,614,063 shares in the last quarter. Orbis Allan Gray Ltd raised its stake in IQVIA by 96.5% during the fourth quarter. Orbis Allan Gray Ltd now owns 1,901,091 shares of the medical research company’s stock worth $428,525,000 after acquiring an additional 933,554 shares in the last quarter. Finally, AQR Capital Management LLC lifted its holdings in shares of IQVIA by 130.2% during the second quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock valued at $245,099,000 after acquiring an additional 879,701 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

IQV has been the topic of several analyst reports. Stifel Nicolaus upped their target price on shares of IQVIA from $220.00 to $276.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. HSBC reissued a “buy” rating and set a $240.00 price target on shares of IQVIA in a report on Monday, July 6th. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday. Morgan Stanley reaffirmed an “equal weight” rating and set a $200.00 price objective (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. Finally, BMO Capital Markets lifted their target price on shares of IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $241.88.

Insider Buying and Selling

In other IQVIA news, insider Keriann Cherofsky sold 558 shares of the company’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the transaction, the insider owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. This represents a 15.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eric Sherbet sold 5,000 shares of the stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the completion of the transaction, the insider owned 20,999 shares in the company, valued at $5,232,110.84. The trade was a 19.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 1.70% of the company’s stock.

IQVIA Stock Up 0.0%

Shares of NYSE IQV opened at $235.09 on Monday. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $251.36. The firm’s 50-day simple moving average is $194.75 and its 200 day simple moving average is $186.82. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. The company has a market cap of $38.70 billion, a price-to-earnings ratio of 29.17, a price-to-earnings-growth ratio of 1.99 and a beta of 1.20.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating the consensus estimate of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. During the same quarter last year, the company posted $2.81 EPS. The company’s quarterly revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, research analysts expect that IQVIA Holdings Inc. will post 11.61 earnings per share for the current fiscal year.

IQVIA announced that its Board of Directors has approved a share buyback program on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s leadership believes its shares are undervalued.

IQVIA News Summary

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: William Blair upgraded IQVIA to “strong buy,” adding to the favorable analyst outlook. Ticker Report article
• Positive Sentiment: Robert W. Baird raised its IQVIA price target to $287, implying substantial upside from the cited trading level. JPMorgan and Stifel Nicolaus also expressed expectations for further appreciation. American Banking News article on Baird price target American Banking News article on JPMorgan forecast American Banking News article on Stifel outlook
• Positive Sentiment: IQVIA’s second-quarter results exceeded expectations, with adjusted earnings of $3.15 per share versus the $3.03 consensus and revenue of $4.37 billion versus $4.30 billion expected. Revenue increased 8.7% year over year, reinforcing the company’s growth profile. IQVIA Q2 2026 earnings call summary
• Neutral Sentiment: Analysts maintain a “moderate buy” consensus, indicating generally favorable sentiment but not unanimous conviction. IQVIA analyst consensus article
• Negative Sentiment: Two insiders sold shares on July 29: Keriann Cherofsky sold 558 shares for approximately $136,827, while Eric Sherbet sold 5,000 shares for about $1.25 million. Although both retain meaningful holdings, the transactions may create short-term investor concern. SEC insider sale filing for Keriann Cherofsky SEC insider sale filing for Eric Sherbet

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.